NCT02362958View on ClinicalTrials.gov

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

January 9, 2015

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
HER2 Positive Breast Cancer
Interventions
DRUG

lapatinib and capecitabine or vinorelbine

lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)

Trial Locations (1)

510080

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02362958 - A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter